These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

377 related items for PubMed ID: 26183802

  • 1. Utility-based criteria for selecting patients with hepatocellular carcinoma for liver transplantation: A multicenter cohort study using the alpha-fetoprotein model as a survival predictor.
    Vitale A, Farinati F, Burra P, Trevisani F, Giannini EG, Ciccarese F, Piscaglia F, Rapaccini GL, Di Marco M, Caturelli E, Zoli M, Borzio F, Cabibbo G, Felder M, Sacco R, Morisco F, Missale G, Foschi FG, Gasbarrini A, Svegliati Baroni G, Virdone R, Chiaramonte M, Spolverato G, Cillo U, Italian Liver Cancer Group.
    Liver Transpl; 2015 Oct; 21(10):1250-8. PubMed ID: 26183802
    [Abstract] [Full Text] [Related]

  • 2. Delta-slope of alpha-fetoprotein improves the ability to select liver transplant patients with hepatocellular cancer.
    Lai Q, Inostroza M, Rico Juri JM, Goffette P, Lerut J.
    HPB (Oxford); 2015 Dec; 17(12):1085-95. PubMed ID: 26373980
    [Abstract] [Full Text] [Related]

  • 3. α-Fetoprotein is a potential survival predictor in hepatocellular carcinoma patients with hepatitis B selected for liver transplantation.
    Zhang Q, Shang L, Zang Y, Chen X, Zhang L, Wang Y, Wang L, Liu Y, Mao S, Shen Z.
    Eur J Gastroenterol Hepatol; 2014 May; 26(5):544-52. PubMed ID: 24614696
    [Abstract] [Full Text] [Related]

  • 4. The relative net health benefit of liver resection, ablation, and transplantation for early hepatocellular carcinoma.
    Spolverato G, Vitale A, Ejaz A, Kim Y, Maithel SK, Cosgrove DP, Pawlik TM.
    World J Surg; 2015 Jun; 39(6):1474-84. PubMed ID: 25665675
    [Abstract] [Full Text] [Related]

  • 5. Identifying patients at higher risk of hepatocellular carcinoma recurrence after liver transplantation in a multicenter cohort study from Argentina.
    Piñero F, Marciano S, Anders M, Orozco Ganem F, Zerega A, Cagliani J, Andriani O, de Santibañes E, Gil O, Podestá LG, McCormack L, Gadano A, Silva M.
    Eur J Gastroenterol Hepatol; 2016 Apr; 28(4):421-7. PubMed ID: 26684693
    [Abstract] [Full Text] [Related]

  • 6. Serological Risk Index Based on Alpha-Fetoprotein and C-Reactive Protein to Indicate Futile Liver Transplantation Among Patients with Advanced Hepatocellular Carcinoma.
    Kornberg A, Schernhammer M, Kornberg J, Friess H, Thrum K.
    Dig Dis Sci; 2019 Jan; 64(1):269-280. PubMed ID: 30259282
    [Abstract] [Full Text] [Related]

  • 7. Homocysteine: A novel prognostic biomarker in liver transplantation for alpha-fetoprotein- negative hepatocellular carcinoma.
    Yang M, Tan W, Yang X, Zhuo J, Lin Z, Cen B, Lian Z, Li H, Lu D, Wei X, Zheng S, Xu X.
    Cancer Biomark; 2020 Jan; 29(2):197-206. PubMed ID: 32623388
    [Abstract] [Full Text] [Related]

  • 8. AFP level and histologic differentiation predict the survival of patients with liver transplantation for hepatocellular carcinoma.
    Yaprak O, Akyildiz M, Dayangac M, Demirbas BT, Guler N, Dogusoy GB, Yuzer Y, Tokat Y.
    Hepatobiliary Pancreat Dis Int; 2012 Jun; 11(3):256-61. PubMed ID: 22672818
    [Abstract] [Full Text] [Related]

  • 9. Combined Hangzhou criteria with neutrophil-lymphocyte ratio is superior to other criteria in selecting liver transplantation candidates with HBV-related hepatocellular carcinoma.
    Xiao GQ, Yang JY, Yan LN.
    Hepatobiliary Pancreat Dis Int; 2015 Dec; 14(6):588-95. PubMed ID: 26663006
    [Abstract] [Full Text] [Related]

  • 10. A method for establishing allocation equity among patients with and without hepatocellular carcinoma on a common liver transplant waiting list.
    Vitale A, Volk ML, De Feo TM, Burra P, Frigo AC, Ramirez Morales R, De Carlis L, Belli L, Colledan M, Fagiuoli S, Rossi G, Andorno E, Baccarani U, Regalia E, Vivarelli M, Donataccio M, Cillo U, Liver Transplantation North Italy Transplant program (NITp) working group.
    J Hepatol; 2014 Feb; 60(2):290-7. PubMed ID: 24161408
    [Abstract] [Full Text] [Related]

  • 11. Is resectable hepatocellular carcinoma a contraindication to liver transplantation? A novel decision model based on "number of patients needed to transplant" as measure of transplant benefit.
    Vitale A, Cucchetti A, Qiao GL, Cescon M, Li J, Ramirez Morales R, Frigo AC, Xia Y, Tuci F, Shen F, Cillo U, Pinna AD.
    J Hepatol; 2014 Jun; 60(6):1165-71. PubMed ID: 24508550
    [Abstract] [Full Text] [Related]

  • 12. Liver transplantation for hepatocellular carcinoma: a model including α-fetoprotein improves the performance of Milan criteria.
    Duvoux C, Roudot-Thoraval F, Decaens T, Pessione F, Badran H, Piardi T, Francoz C, Compagnon P, Vanlemmens C, Dumortier J, Dharancy S, Gugenheim J, Bernard PH, Adam R, Radenne S, Muscari F, Conti F, Hardwigsen J, Pageaux GP, Chazouillères O, Salame E, Hilleret MN, Lebray P, Abergel A, Debette-Gratien M, Kluger MD, Mallat A, Azoulay D, Cherqui D, Liver Transplantation French Study Group.
    Gastroenterology; 2012 Oct; 143(4):986-94.e3; quiz e14-5. PubMed ID: 22750200
    [Abstract] [Full Text] [Related]

  • 13. Predictive Value of Alpha-fetoprotein in the Survival of Living Donor Liver Transplantation Recipients for Hepatocellular Carcinoma.
    Jiang L, Liao A, Yan L, Li B, Zhu W, Wen T.
    Hepatogastroenterology; 2014 May; 61(131):747-51. PubMed ID: 26176068
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Predicting survival after liver transplantation using up-to-seven criteria in patients with hepatocellular carcinoma.
    de Ataide EC, Garcia M, Mattosinho TJ, Almeida JR, Escanhoela CA, Boin IF.
    Transplant Proc; 2012 Oct; 44(8):2438-40. PubMed ID: 23026614
    [Abstract] [Full Text] [Related]

  • 16. Section 5. Further expanding the criteria for HCC in living donor liver transplantation: when not to transplant: SNUH experience.
    Lee KW, Yi NJ, Suh KS.
    Transplantation; 2014 Apr 27; 97 Suppl 8():S20-3. PubMed ID: 24849825
    [Abstract] [Full Text] [Related]

  • 17. Validation of the AFP model as a predictor of HCC recurrence in patients with viral hepatitis-related cirrhosis who had received a liver transplant for HCC.
    Notarpaolo A, Layese R, Magistri P, Gambato M, Colledan M, Magini G, Miglioresi L, Vitale A, Vennarecci G, Ambrosio CD, Burra P, Di Benedetto F, Fagiuoli S, Colasanti M, Maria Ettorre G, Andreoli A, Cillo U, Laurent A, Katsahian S, Audureau E, Roudot-Thoraval F, Duvoux C.
    J Hepatol; 2017 Mar 27; 66(3):552-559. PubMed ID: 27899297
    [Abstract] [Full Text] [Related]

  • 18. Use of sorafenib in patients with hepatocellular carcinoma before liver transplantation: a cost-benefit analysis while awaiting data on sorafenib safety.
    Vitale A, Volk ML, Pastorelli D, Lonardi S, Farinati F, Burra P, Angeli P, Cillo U.
    Hepatology; 2010 Jan 27; 51(1):165-73. PubMed ID: 19877181
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Hepatocyte nuclear factor 1β is a novel prognostic marker independent of the Milan criteria in transplantable hepatocellular carcinoma: a retrospective analysis based on tissue microarrays.
    Shim JH, Lee HC, Han S, Kang HJ, Yu E, Lee SG.
    Liver Transpl; 2013 Mar 27; 19(3):336-45. PubMed ID: 23203386
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.